NGS-based tumor profiling solution, 5/1:84

Illumina’s TruSight Tumor, for NGS-based somatic variant detection in solid tumors, provides optimized amplicon-based library preparation of 26 oncogenes and tumor suppressor genes selected for their involvement in common solid tumors, including lung, colon, melanoma, gastric, and ovarian cancer.

TruSight Tumor also offers a comprehensive NGS-based tumor profiling solution that provides a broader and more cost-effective view of tumor heterogeneity than genotyping-based methods. Researchers can simultaneously detect somatic changes in multiple genes across the tumor genome as well as emerging biomarkers implicated in pharmaceutical clinical trials. Designed for use with formalin-fixed paraffin-embedded samples, TruSight Tumor enables high levels of sensitivity for minor allele detection, with limited DNA input requirements.

TruSight Tumor is the first content set designed for somatic variant detection on the Illumina MiSeq platform. TruSight content sets are for high-performance targeted sequencing and offer exceptional performance in the capture and sequencing of targeted genomic regions.

TruSight content sets are for research use only and not intended for diagnostic use.

Illumina, 858-202-4566